Generic and biosimilar timing isn’t a guess—it’s a discipline.
If you’re managing formularies, contracts, or patient access, you’ve probably felt the pressure: a brand’s “exclusivity” is expiring, competitors are circling, and internal stakeholders w…

Before a drug ever hits a press release, the real competition is already in motion.
Most teams only react once a pipeline is public—when a company files a press release, posts trial results, or publishes a slide deck. But in pharma, “public” is often…

20 Years on Paper: The Real Guide to Drug Patent Duration in the United States
Most people think drug patent life is a simple countdown: 20 years from filing. In reality, the clock is more like a relay race—multiple “start times,” multiple legal events…

Pick the Right Patent—or Leave Billions on the Table: The One-Patent-Per-Product Rule and PTE Selection Strategy
In pharma, the difference between winning and losing isn’t always the science. Often, it’s the paperwork—specifically, which patent you cho…

Most 505(b)(2) strategies fail before the first filing—because teams treat it like a regulatory checkbox, not a business model.
If you’re a CDMO, specialty lab, or service provider supporting 505(b)(2) follow-on drugs, you’re not just helping sponsors …

Combining Lipitor (atorvastatin) with aspirin has been a topic of interest for healthcare professionals due to their common… https://www.Drugchatter.com/chat/18474/what-are-the-effects-of-combining-lipitor-and-aspirin/

Pharma doesn’t always “block” generics with one big move. More often, it’s a layered strategy—stacking exclusivities, tweaking drug classifications, and extending market control long after the original patent cliff.
That’s the core story behind “Build …

India’s “drug patent clock” isn’t a clock at all—it’s a maze. Here’s how long protection really lasts.
If you’ve ever heard that a drug patent in India “lasts 20 years,” you’ve heard the headline—not the reality.
In practice, the effective protection w…